Indies Pharma Jamaica Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Indies Pharma Jamaica yıllık ortalama 9.4% oranında kazançlarını artırırken, Healthcare sektöründe kazançlar growing at 14.2% annual. Gelirler growing yılda ortalama 9.3% oranında artmaktadır. Indies Pharma Jamaica'in özkaynak karlılığı 17.3% ve net marjı 19%'dir.

Anahtar bilgiler

9.4%

Kazanç büyüme oranı

8.6%

EPS büyüme oranı

Healthcare Sektör Büyümesi	-2.9%
Gelir büyüme oranı	9.3%
Özkaynak getirisi	17.3%
Net Marj	19.0%
Son Kazanç Güncellemesi	31 Jul 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Indies Pharma Jamaica nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

JMSE:INDIES Gelir, gider ve kazançlar (JMD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Jul 24	1,136	216	344
30 Apr 24	1,139	256	344
31 Jan 24	1,069	217	342
31 Oct 23	1,055	213	312
31 Jul 23	997	206	339
30 Apr 23	962	194	300
31 Jan 23	981	230	281
31 Oct 22	937	221	274
31 Jul 22	941	252	276
30 Apr 22	884	222	270
31 Jan 22	836	171	262
31 Oct 21	847	168	244
31 Jul 21	833	152	251
30 Apr 21	791	159	240
31 Jan 21	796	215	230
31 Oct 20	766	207	246
31 Jul 20	719	177	265
30 Apr 20	769	161	295
31 Jan 20	755	124	314
31 Oct 19	729	131	295
31 Jul 19	763	153	304
30 Apr 19	696	150	269
31 Jan 19	653	143	224
31 Oct 18	636	120	210
31 Jul 18	622	123	221
30 Apr 18	647	135	191
31 Jan 18	635	135	190
31 Oct 17	620	137	186
31 Oct 16	587	79	248

Kaliteli Kazançlar: INDIES yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: INDIES 'nin mevcut net kar marjları (19%) geçen yılın (20.7%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: INDIES şirketinin kazancı son 5 yılda yılda 9.4% oranında arttı.

Büyüme Hızlandırma: INDIES 'un son bir yıldaki kazanç büyümesi ( 4.5% ) 5 yıllık ortalamasının ( 9.4% /yıl) altındadır.

Kazançlar vs. Sektör: INDIES geçen yılki kazanç büyümesi ( 4.5% ) Healthcare sektörünün 20.1% performansını geride bırakmadı.

Özkaynak Getirisi

Yüksek ROE: INDIES 'nin Özsermaye Getirisi ( 17.3% ) düşük olarak değerlendiriliyor.

Indies Pharma Jamaica Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: EPS: JA$0.03 (vs JA$0.06 in 3Q 2023)

Second quarter 2024 earnings released: EPS: JA$0.053 (vs JA$0.02 in 2Q 2023)

First quarter 2024 earnings released: EPS: JA$0.047 (vs JA$0.044 in 1Q 2023)

Full year 2023 earnings released: EPS: JA$0.16 (vs JA$0.17 in FY 2022)

Full year 2023 earnings released: EPS: JA$0.16 (vs JA$0.17 in FY 2022)

Third quarter 2023 earnings released: EPS: JA$0.06 (vs JA$0.05 in 3Q 2022)

Recent updates

Third quarter 2024 earnings released: EPS: JA$0.03 (vs JA$0.06 in 3Q 2023)

Investor sentiment improves as stock rises 21%

Second quarter 2024 earnings released: EPS: JA$0.053 (vs JA$0.02 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Indies Pharma Jamaica Limited, Annual General Meeting, May 29, 2024

First quarter 2024 earnings released: EPS: JA$0.047 (vs JA$0.044 in 1Q 2023)

Full year 2023 earnings released: EPS: JA$0.16 (vs JA$0.17 in FY 2022)

Full year 2023 earnings released: EPS: JA$0.16 (vs JA$0.17 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Insufficient new directors

Third quarter 2023 earnings released: EPS: JA$0.06 (vs JA$0.05 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JA$0.02 (vs JA$0.05 in 2Q 2022)

Investor sentiment improves as stock rises 19%

Upcoming dividend of JA$11.33 per share at 3.4% yield

Investor sentiment improves as stock rises 26%

First quarter 2023 earnings released: EPS: JA$0.04 (vs JA$0.04 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: JA$0.05 (vs JA$0.03 in 3Q 2021)

Second quarter 2022 earnings released: EPS: JA$0.05 (vs JA$0.01 in 2Q 2021)

Upcoming dividend of JA$0.11 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS JA$0.01 (vs JA$0.04 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS JA$0.02 (vs JA$0.05 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS JA$0.04 (vs JA$0.03 in 1Q 2020)

Upcoming Dividend of JA$0.11 Per Share

New 90-day high: JA$2.89

Full year 2020 earnings released: EPS JA$0.15 (vs JA$0.12 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: JA$2.31

Full year 2020 earnings released: EPS JA$0.15

New 90-day low: JA$2.43

Indies Pharma Jamaica Limited Announces Appointment of Directors

Third quarter earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin